ClinicalTrials.gg
CompletedNCT06924632Updated May 18, 2026

Efficacy & Safety of Minoxidil SL Tablets in Men With AGA

A Phase 3 interventional study of Minoxidil and Placebo in Androgenetic Alopecia and Male Pattern Baldness, sponsored by Samson Clinical Operations Pty Ltd. Completed at 3 sites in Australia. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by Samson Clinical Operations Pty Ltd · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing minoxidil in Alopecia — 10 open to participants now, 12 under way, 3 of them phase 3. Minoxidil · Alopecia.

Enrollment
8th of 31
142 · median 60
Started
2025
with 4 others
Phase 3
8 of 31
2 open now
Registered
23rd of 31
by date

Among the 31 studies testing minoxidil in Alopecia, this one is the 8th largest by enrollment, is one of 5 that started in 2025, is one of 8 in phase 3, and was the 23rd registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 129 are open to participants now.

Browse Alopecia studies →

Open to participants now

10 of the 31 studies testing minoxidil in Alopecia are open now, in 5 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About minoxidil

Minoxidil: first FDA approval 1979 (LONITEN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing minoxidil in Alopecia, or all of them as a file.
02

Study summary

This is a phase 3, multicentre, randomised, double-blinded, placebo-controlled study examining the safety and efficacy of 2.5 mg sublingual (SL) minoxidil tablets taken twice daily in the treatment of androgenetic alopecia (AGA) in men. The duration of study participation is 32 weeks including screening and safety follow up.

The primary efficacy objective is to determine whether treatment with 2.5 mg SL tablets twice daily increases the number of hairs in men with AGA over 24 weeks. The primary safety objective is to evaluate the safety and tolerability of 2.5 mg SL tablets administered twice daily over 24 weeks.

03

Conditions studied

  • Androgenetic Alopecia
  • Male Pattern Baldness

Browse trials for

Keywords

  • Hair Loss
  • Male Pattern Balding
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cisgender males of at least 18 years of age (inclusive) at the time of Screening.
  • In good general health in the opinion of the Investigator.
  • Presence of androgenetic alopecia with hair density reduction in the centroparietal area or vertex of the scalp classified as Norwood-Hamilton Type III vertex, IV, V or VI.
  • Willing and able to attend all study visits and comply with treatment plan and required study procedures including scalp tattooing and hair trimming.
  • Willing to maintain the same hair style, hair colour, and hair length in non-balding areas.
  • Able to comprehend and willing to sign and date a written patient form (PICF).

Exclusion criteria

Exclusion Criteria:

  • Norwood-Hamilton Type IIIa, IVa, and Va grades (i.e. participants must have vertex balding).
  • Use of topical minoxidil, oral minoxidil, dutasteride, finasteride, drugs with anti-androgenetic or androgenetic properties, or medications that cause hypertrichosis or hypotrichosis within the 6 months prior to enrolment.
  • Laser treatment of the scalp within 3 months prior to enrolment.
  • History of scalp micropigmentation or hair restoration surgery.
  • Use of wigs, hair extensions, hair pieces, or hair weaves at time of enrolment.
  • Use of anti-hypertensive medication.
  • Current participation in any other drug or medical device trial, which includes administration of an investigational study medication or medical device, or participation in such a trial within 3 months or 5 half-lives of the investigational product, whichever is longer, prior to receiving the first dose.
  • History of or allergies to minoxidil or any of the contained in the study medication.
  • Known allergy or sensitivity to tattoo ink.
  • Dermatological disorder (e.g. eczema, psoriasis) or infection affecting the target area (vertex or centroparietal area).
  • Scalp characteristics, including scarring, that may interfere with examinations.
  • Medical condition which adversely affects hair loss.
  • Specific underlying conditions (e.g. cardiovascular disease, congestive cardiac failure, cardiac arrhythmia, systemic lupus erythematosus, history of phaeochromocytoma, pulmonary hypertension secondary to mitral stenosis, minoxidil hypersensitivity), findings from medical history, clinical laboratory tests, , or vital signs that, in the opinion of the Investigator, could interfere with the objectives of the study or put the participant at risk.
  • Moderate to severe renal or hepatic impairment.
  • Hypotension (blood pressure less than 90/60 mmHg) or a history of significant symptomatic postural hypotension.
  • Untreated or uncontrolled hypertension (blood pressure greater than 150/90 mmHg, not stable on current medication for the past 3 months).
  • History or evidence of hair loss other than androgenetic alopecia.
  • Unwilling to comply with all study procedures and assessments.
  • Scalp hair length less than \~2.5 cm
  • History of alcohol and/or substance abuse, or drug-abuse disorders.
  • Major surgery within 4 weeks prior to the screening evaluation, or planned surgery prior to completion of all study procedures.
  • Site employees or immediate family members of study site employees.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
142 participants (actual)

Study arms

  • Experimental
    2.5 mg Sublingual Minoxidil BID

    2.5 mg sublingual minoxidil to be taken twice a day, once in the AM and once in the PM.

    Drug: Minoxidil

  • Placebo comparator
    Placebo BID

    placebo to be taken sublingually twice a day, once in the AM and once in the PM.

    Drug: Placebo

Interventions

  • 2.5 mg Sublingual Minoxidil Tablet

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Mean Change in Non-vellus Target Area Hair Counts (TAHC)

    Mean change in the vertex scalp non-vellus TAHC from baseline to week 24.

    Time frame: 24 Weeks

07

Study locations

3 sites
  • Premier Specialists Pty Ltd
    Kogarah, New South Wales 2217, Australia
  • DIRECT
    East Melbourne, Victoria 3002, Australia
  • DIRECT
    Pascoe Vale, Victoria 3044, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in May 2026, 10 months.

Of 28 phase 3 interventional studies under Alopecia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2025
First posted
Apr 11, 2025
StartActual
Jul 14, 2025
Primary completionActual
May 15, 2026
CompletionActual
May 15, 2026
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06924632
Lead sponsor
Samson Clinical Operations Pty Ltd
Responsible party
Sponsor
First posted
Apr 11, 2025
Start date
Jul 14, 2025
Primary completion
May 15, 2026
Completion
May 15, 2026
Last update
May 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Minoxidil

Start the discussion